top of page


Hyperthermia Therapy is a Non-Invasive Integrated Therapy In the Fight Against Cancer.

There are just a few cancer centres in North America to offer Hyperthermia (Modulated Electro-hyperthermia using the Oncotherm EHY-2000), advanced technology from Germany and a major breakthrough in integrative cancer therapy. Now, Canadians no longer have to travel overseas to receive the most advanced, integrated and potentially life-saving cancer care.


Hyperthermia has proven its exceptional value in cancer treatment. In Germany, hyperthermia, (modulated Electro-hyperthermia using the Oncotherm-2000 Plus device)  has for many decades been part of the standard of care for cancer treatment, used concurrently with chemotherapy and radiation. At present, there are over 100,000 hyperthermia treatments (using the oncotherm-200 plus device) provided worldwide every year, to patients with a variety of different cancer types and stages of disease.

Cancer care physicians, use hyperthermia in conjunction with other evidence-based therapies that, when strategically integrated, provide the best outcomes for their patients.



In oncology, the term ‘hyperthermia’ refers to the treatment of malignant (cancerous) diseases by administering heat in various ways. According to the National Cancer Institute (NCI), scientists believe that this non-invasive heat therapy may help shrink tumors with minimal injury to normal tissue. The results from human clinical trials indicate that hyperthermia is both an effective complementary treatment to, and a strong sensitizer of, radiotherapy and chemotherapy. Worldwide, evidence for the benefits of hyperthermia in integrated cancer care continues to mount, establishing a clear rationale for the use of hyperthermia in cancer treatment.


Loco-Regional Hyperthermia-LRHT (Modulated Electro-hyperthermia using the Oncothermia EHY-2000 device) employs a modulated electric field current to selectively deliver a controlled energy dose to a localized treatment area. A mobile electrode is positioned on the treatment area, while a second stationary electrode remains in a fixed position below the patient, integrated within the therapy bed. Operating at a carrier frequency of 13.56 MHz, this capacitive coupled circuit delivers energy directly to the malignant cells.

One of the most significant effects of LRHT is its ability to sensitize cancer cells to chemotherapy (chemo-sensitization). The positive results of phase II & III clinical trials have established that LRHT with chemotherapy is a novel clinical modality that allows the chemotherapy to be better targeted within the heated tumor.

The aim of LRHT is to achieve the optimal thermal dose in the tumor tissue. This is generally defined as a modest elevation of temperature to a range of 40° to 45°C. without exceeding the tolerance limits of the surrounding normal tissues, which means very low risk of healthy tissue damage.

When focused heating is used to raise the temperature of tumor tissue, it generates several physiological advantages to treating the malignant tumor:

  • Reduced tumor growth and invasion: Heat damages or weakens the proteins and structures within cells of the tumor, slowing the growth and spread of the tumor.

  • Chemo-sensitization & targeted drug uptake: Heat increases blood flow through the weakened tumor allowing targeted uptake of chemotherapy, thereby amplifying the anti-cancer effects on the tumor while protecting healthy tissue.

  • Radio-sensitization & apoptosis induction: The tumor environment is pathologically hypoxic (has low oxygen levels) which contributes to resistance to radiation therapy. Heating raises oxygen levels in tumors (via increased blood flow) so the cancer can be more effectively treated by radiation therapy, stimulating apoptosis (cancer cell death) and tumor necrosis (destruction).

  • Enhanced anti-angiogenesis: LRHT has been shown to enhance the effect of anti-angiogenic drugs (agents used to inhibit tumor blood vessel formation) commonly used in metastatic disease (e.g. bevacizumab).

  • Immune induction: The body senses fever and can stimulate the immune system (via increased expression and release of heat shock proteins), activating and employing the body’s natural innate immune mechanisms, thereby assisting the anti-tumor response.

  • Activation of tumor suppressor genes: LRHT has been demonstrated to activate p53 – a tumor suppressor gene that is silenced in most cancers. It codes for a critical molecule that is responsible for inducing cancer cell cycle arrest and apoptosis, as well as DNA repair of abnormal cells.

In addition, LRHT has application in the post-surgical setting to treat potential rogue cells liberated via biopsy or surgery.


Clinical trials have demonstrated that LRHT presents minimal risk and limited adverse side effects. Heating the tumor has minimal effect on adjacent healthy tissue. Healthy tissue has the ability to dissipate the heat efficiently while cancerous tissue is incapable of this due to its more primitive blood supply and dense unorganised cellular makeup. . Surface effects are generally limited to slight reddening of the skin. Patients are monitored regularly by our physicians and nurses throughout the duration of treatment to monitor for discomfort.


LRHT is intended for use as an adjunct to (i.e. combined with) chemotherapy, radiation and other conventional cancer treatments.


LRHT is a treatment for solid tumor cancers, with indications for both primary and metastatic malignancies, as demonstrated by phase II & III clinical trials. 


Hyperthermia is used as part of a coordinated, focused and comprehensive integrative cancer approach. To be able to advise integrative cancer therapy, physicians will need to carry out an evaluation of your cancer type, stage, and location.

There are many integrative cancer therapy options and the right type of care is individualized to the unique needs of the patient.



Szasz, O. Essentials of Oncothermia. Conference Papers in Medicine. 2013 April: Article ID159570;20 pages.

Szasz, O. Oncothermia as Personalized Treatment Option. Conference Papers in medicine. 2013 April: Article ID9413364;6 pages.

Linthorst M, van Geel AN, et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother Oncol. 2013 Nov;109(2):188-93.

Jung, HJ, Seo YR. Protective effects of thioredoxin-mediated p53 activation in response to mild hyperthermia. Oncology Reports. 2012;Mar;27(3):650-6.

Mantel F, Frey B, et al. Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol. 2010 Nov;186(11):587-99.

Rubovsky G, Nagy T, et al. Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia. Pathol Oncol Res. 2013 Jan;19(1):119-22.

Wismeth C, Dudel C, et al. Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results. J Neurooncol. 2010 Jul;98(3):395-405.

Westermann A, Jones E, et al. First Results of Triple-Modality Treatment Combining Radiotherapy, Chemotherapy, and Hyperthermia for the Treatment of Patients with Stage IIB, III and IVA Cervical Carcinoma. Cancer. 2005 Aug;104(4):763–770.

Zee, J. Heating The Patient: A Promising Approach. Annals of Oncology. 2002;13:1173-1184.

Overguard J, Gonzalez D. Hyperthermia as an Adjuvant to Radiation Therapy of Recurrent or Metastatic Malignant Melanoma. A Multicentre Randomized Trial by the European Society for

Hyperthermic Oncology. Int. J Hyperthermia. 1996;12(1):3-20.

Datta N, Bose K. Head and Neck Cancers: Results of Thermoradiotherapy Versus Radiotherapy. Int. J Hyperthermia. 199;6(3):479-486.

Hullgol N, Gupta S, Sridhar CR. Hyperthermia with Radiation in the Treatment of Locally Advanced Head and Neck Cancer: A Report of Randomized Trial. J Cancer Research and Therapeutics. 2010 Oct;6(4):492-496.

Issels R, Lindner L, et al. Neo-adjuvant Chemotherapy Alone or with Regional Hyperthermia for Localised High-Risk Soft-Tissue Sarcoma: A Randomized Phase 3 Multicenter Study. Lancet. 2010; Epub 2010 Apr 29.

Gong W, Wang Z. Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull. 2011;34(7):1058-64.

Silva AC, Oliveira TR, et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomedicine. 2011;6:591-603.

Dani A, Varkonyi A, et al. Clinical Study for Advanced Pancreas Cancer Treated by Oncothermia. Forum Hyperthermie. 2008;13-19.

Dowes F, Bogovic J. Whole-Body Hyperthermia in Combination with Platinum-Containing Drugs in Patients with Recurrent Ovarian Cancer. Int J Clin Oncol. 2004;9:85-91.

bottom of page